Urothelial Carcinoma Bladder Clinical Trials

44 clinical trials for Urothelial Carcinoma Bladder across international registries, including 13 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors — RECRUITING · PHASE1
• Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer — RECRUITING · PHASE2
• Intervention of Bladder Cancer by CAR-T — RECRUITING · PHASE1
• A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 — RECRUITING · PHASE1
• Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy — RECRUITING · PHASE2
• Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer — RECRUITING · PHASE1
• Preoperative Physical Activity Before Radical Cystectomy and the Impact on Morbidity — RECRUITING · NA
• A Study of VET3-TGI in Patients With Solid Tumors — RECRUITING · PHASE1
• Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) — RECRUITING · PHASE3
• Bladder EpiCheck European Haematuria Study — RECRUITING
• Renal Retention in High Grade Upper Tract Urothelial Cancer — RECRUITING · PHASE2
• Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma — RECRUITING · PHASE2
• 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma — RECRUITING · PHASE2
• A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC — NOT_YET_RECRUITING · PHASE1
• Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02) — ACTIVE_NOT_RECRUITING
• A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer — ACTIVE_NOT_RECRUITING · PHASE3
• Calcium Electroporation for Urinary Bladder Tumors: A First-in-Human Feasibility, Safety, and Early Response Trial — NOT_YET_RECRUITING · PHASE1
• Phase Ib of L-NMMA and Pembrolizumab — COMPLETED · PHASE1
• IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC — COMPLETED · PHASE2
• Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant — TERMINATED · PHASE1
• A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy — WITHDRAWN · PHASE3
• A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT — WITHDRAWN · PHASE3
• A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer — NOT_YET_RECRUITING · PHASE3
• A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer — ACTIVE_NOT_RECRUITING · PHASE3
• A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) — COMPLETED · PHASE1
• Evaluating Bladder CARE™, a New Non-Invasive Urine Test, for Bladder Cancer Detection in Inconclusive Cases — ACTIVE_NOT_RECRUITING
• Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC. — NOT_YET_RECRUITING · PHASE1
• JAM3 as a Prognostic Biomarker in Muscle-Invasive Urothelial Carcinoma: Correlation With Therapeutic Response, and Survival Outcomes — NOT_YET_RECRUITING
• Bladder Cancer Adjuvant Radiotherapy Trial — ACTIVE_NOT_RECRUITING · PHASE3
• Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) — COMPLETED · PHASE3
• A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer — TERMINATED · PHASE3
• A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma — COMPLETED · PHASE1
• Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss — WITHDRAWN · PHASE1
• A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma — TERMINATED · PHASE2
• Effect of Intravesical B.C.G and Gemcitabine on Semen Quality and Testicular Volume — OTHER · PHASE4
• A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer — COMPLETED · PHASE2
• Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer — OTHER · PHASE2
• Urothelial Cancer Tumor Bio-markers and Physical-spectroscopic Characteristic — OTHER
• Adjuvant Radiotherapy Versus Observation After Radical Cystectomy in High Risk Urothelial Bladder Cancer — OTHER · NA
• En Bloc Bladder Tumor Resection: Prospective Randomized Study — OTHER · NA

Refine this search